Tutorials › Bioavailability and Bioequivalence › Dose Normalization Under Unequal Administered Doses

Home  /  Tutorials  /  Absolute and Relative Bioavailability

Absolute and Relative Bioavailability · Tutorial 4 of 399

Dose Normalization Under Unequal Administered Doses

Calculate absolute and relative bioavailability across unequal doses, and assess when dose-normalized AUC provides a valid comparison.

Beginner 9 min read

What You'll Learn

  • Calculate dose-normalized AUC for unequal administered doses.
  • Estimate absolute bioavailability using oral and IV data at different doses.
  • Compare relative bioavailability when test and reference doses differ.
  • Explain how dose proportionality supports dose normalization.
  • Identify when dose-normalized comparisons are not justified.

Why Normalize for Dose?

An AUC reflects both how much drug was administered and how much exposure is produced per unit of administered dose. Therefore, a larger AUC does not by itself show greater bioavailability when doses differ: the larger exposure may simply result from the larger dose. Dose normalization expresses AUC per unit of dose, allowing a comparison across doses when the pharmacokinetics support that scaling.

The central condition is dose proportionality over the doses being compared. In practical terms, dose proportionality means that AUC changes in direct proportion to administered dose: doubling the dose doubles AUC, and the ratio of AUC to dose remains constant. This is an assumption to assess, not an automatic property of every drug, route, or dose range.

Definition: For a specified route, formulation, and AUC measure, the dose-normalized AUC is \(\mathrm{AUC}/D\), where \(D\) is the administered dose. It describes exposure per unit of administered dose. When the relevant pharmacokinetics are dose proportional, it can be used to compare exposure across unequal doses.

For absolute bioavailability, oral exposure is compared with IV exposure. For relative bioavailability, exposure from one formulation or regimen is compared with a reference. If the doses are unequal, the relevant comparison is between dose-normalized AUC values, not raw AUC values. The AUCs must also be comparable: they should use the same analyte and a consistent AUC definition, and be measured under conditions that permit the intended comparison.

How Dose Normalization Supports Bioavailability Ratios

A short model explains both the calculation and its key condition. Let \(D\) denote administered dose, \(F\) the fraction of that dose reaching systemic circulation, and \(CL\) systemic clearance. Under linear pharmacokinetics, with clearance stable across the comparison, total exposure is

$$ \mathrm{AUC}=\frac{F D}{CL}. $$

Dividing by dose gives the exposure per unit administered dose. The next step is valid only if \(F\) and \(CL\) are not changing with dose over the range being compared.

$$ \frac{\mathrm{AUC}}{D}=\frac{F}{CL}. $$

For absolute bioavailability, IV administration is treated as the reference route, with \(F_{\mathrm{IV}}=1\). If clearance is the same for both routes, then the ratio of dose-normalized oral and IV AUCs estimates the absolute bioavailability \(F\):

$$ F = \frac{\mathrm{AUC}_{\mathrm{oral}}/D_{\mathrm{oral}}} {\mathrm{AUC}_{\mathrm{IV}}/D_{\mathrm{IV}}}. $$

For a test and reference formulation, dose-normalized AUCs give the relative bioavailability ratio when the comparison conditions are appropriate. With the same route and stable clearance, the ratio reflects the relative systemic availability of the two formulations:

$$ F_{\mathrm{rel}} = \frac{\mathrm{AUC}_{\mathrm{test}}/D_{\mathrm{test}}} {\mathrm{AUC}_{\mathrm{ref}}/D_{\mathrm{ref}}}. $$

Both equations are dimensionless ratios. If AUC is measured in mg·h/L and dose in mg, each dose-normalized AUC has units h/L; dividing one by the other cancels those units.

Worked Calculations

Worked Example: Absolute Bioavailability With Unequal Oral and IV Doses

In a hypothetical comparison, an oral dose of 100 mg produces an AUC of 18 mg·h/L. An IV dose of 20 mg produces an AUC of 12 mg·h/L. Calculate absolute bioavailability, assuming the conditions needed for dose normalization hold.

First calculate each dose-normalized AUC:

$$ \frac{\mathrm{AUC}_{\mathrm{oral}}}{D_{\mathrm{oral}}} = \frac{18\ \mathrm{mg\cdot h/L}}{100\ \mathrm{mg}} = 0.180\ \mathrm{h/L}, \qquad \frac{\mathrm{AUC}_{\mathrm{IV}}}{D_{\mathrm{IV}}} = \frac{12\ \mathrm{mg\cdot h/L}}{20\ \mathrm{mg}} = 0.600\ \mathrm{h/L}. $$

Then take their ratio:

$$ F=\frac{0.180\ \mathrm{h/L}}{0.600\ \mathrm{h/L}}=0.300. $$

The estimated absolute bioavailability is 0.300, or 30.0%. This estimate is supported only if AUC is dose proportional across the relevant doses, systemic clearance is comparable, and the AUC measurements are suitable for comparison. In particular, the raw AUC of 18 mg·h/L cannot be compared directly with 12 mg·h/L as if the doses were equal.

Worked Example: Relative Bioavailability With Unequal Formulation Doses

In a hypothetical study, a test formulation is administered at 150 mg and produces an AUC of 27 mg·h/L. A reference formulation is administered at 100 mg and produces an AUC of 24 mg·h/L. Estimate relative bioavailability, assuming the same route, comparable measurement conditions, and dose proportionality for both formulations over these doses.

The normalized AUCs are:

$$ \frac{\mathrm{AUC}_{\mathrm{test}}}{D_{\mathrm{test}}} = \frac{27}{150} = 0.180\ \mathrm{h/L}, \qquad \frac{\mathrm{AUC}_{\mathrm{ref}}}{D_{\mathrm{ref}}} = \frac{24}{100} = 0.240\ \mathrm{h/L}. $$

The relative bioavailability estimate is:

$$ F_{\mathrm{rel}} = \frac{0.180}{0.240} = 0.750. $$

Thus, the estimated dose-normalized exposure for the test formulation is 75.0% of that for the reference. This is a relative exposure estimate under the stated assumptions; the calculation alone does not establish whether the formulations meet any particular acceptance criterion.

Worked Example: Checking Whether Dose Normalization Is Supported

Suppose hypothetical dose-ranging data for one formulation are 50 mg with AUC 10 mg·h/L and 100 mg with AUC 25 mg·h/L. Is it justified to compare these observations by dose normalization?

Calculate AUC per dose at each level:

$$ \frac{10}{50}=0.200\ \mathrm{h/L}, \qquad \frac{25}{100}=0.250\ \mathrm{h/L}. $$

The normalized values differ by 0.050 h/L; the value at 100 mg is 25% larger than the value at 50 mg. Equivalently, doubling the dose from 50 mg to 100 mg is associated with an AUC increase from 10 to 25 mg·h/L, not a doubling to 20 mg·h/L. These data do not support dose proportionality across this range. Simply dividing each AUC by dose would produce numbers, but would not justify treating them as a valid comparison of exposure at a common dose. A comparison at matched doses or further characterization of the dose-exposure relationship would be needed.

Assumptions, Diagnostics, and Alternatives

Dose normalization is a scaling operation, not a correction that makes unlike conditions equivalent. Before interpreting a normalized ratio, check that the assumptions connect the calculation to the intended bioavailability quantity:

  • Dose proportionality: within the dose range used, AUC should be proportional to administered dose for the route or formulation being normalized. Dose-ranging data can help assess whether AUC/D is reasonably stable.
  • Comparable clearance: for an absolute or relative ratio, clearance should not differ in a way that explains the exposure difference. Route comparisons generally rely on the same drug and comparable systemic clearance.
  • Comparable AUC measurement: use the same AUC definition and analyte, with adequate sampling to estimate it. Differences in measurement or incomplete exposure profiles can distort the ratio.
  • Stable comparison conditions: factors that change exposure, such as the study conditions or a change in the administered product, must not be confounded with the dose difference.

A useful diagnostic is to examine AUC against dose in the relevant range. Under dose proportionality, AUC/D should be approximately constant, allowing for expected measurement variability. A systematic increase or decrease in AUC/D, or a pattern where doubling dose does not approximately double AUC, warns against simple normalization. A single pair of unequal-dose observations cannot by itself establish that dose proportionality holds; supporting dose-ranging knowledge or data may be needed.

When the doses can be matched, a same-dose comparison avoids the need to scale AUC across dose levels. When doses cannot be matched, dose-normalized AUC is a useful alternative only if proportionality and the other comparison assumptions are defensible. If those assumptions are not supported, neither dividing by dose nor comparing raw AUC resolves the issue; the dose-exposure relationship must be addressed before drawing the intended conclusion.

Common pitfall: “The test AUC is larger, so the test formulation has greater bioavailability.” This reasoning ignores dose. A larger administered dose can produce a larger AUC even when exposure per unit dose is lower. Compare dose-normalized AUCs when the required assumptions hold; if dose proportionality is not supported, do not interpret the normalized ratio as a valid correction.

Check Your Understanding

Use the definitions and assumptions above to answer each question. Solutions are included after the questions.

  1. A hypothetical oral dose of 80 mg gives an AUC of 16 mg·h/L. An IV dose of 20 mg gives an AUC of 10 mg·h/L. Calculate absolute bioavailability, assuming the required conditions hold.
  2. A test product at 200 mg gives an AUC of 40 mg·h/L; a reference at 100 mg gives an AUC of 30 mg·h/L. Calculate relative bioavailability under the dose-proportionality assumption.
  3. At doses of 40 mg and 80 mg, AUCs are 8 and 16 mg·h/L. What do the normalized values suggest about dose proportionality across these doses?
  4. Why is it not valid to conclude that a formulation has greater bioavailability solely because its AUC is larger when its dose is also larger?

Solutions. (1) The oral normalized AUC is \(16/80=0.200\) h/L and the IV normalized AUC is \(10/20=0.500\) h/L, so \(F=0.200/0.500=0.400\), or 40.0%. (2) The test normalized AUC is \(40/200=0.200\) h/L and the reference normalized AUC is \(30/100=0.300\) h/L, so \(F_{\mathrm{rel}}=0.200/0.300=0.667\), or 66.7%. (3) Both normalized values equal \(0.200\) h/L: \(8/40=16/80=0.200\). This is consistent with dose proportionality across the two observations, although two points alone do not establish it generally. (4) A larger dose can cause a larger AUC even if exposure per unit dose is unchanged or lower. The dose must be accounted for, and interpreting normalized AUC requires dose proportionality.

Previous

Next

Back to Tutorials